Gastric cancer with synchronous and metachronous hepatic metastasis predicted by enhancement pattern on multiphasic contrast-enhanced CT

2018 ◽  
Vol 108 ◽  
pp. 165-171
Author(s):  
Daisuke Tsurumaru ◽  
Yusuke Nishimuta ◽  
Toshio Muraki ◽  
Yoshiki Asayama ◽  
Akihiro Nishie ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Hepatic Metastasis ◽  
Enhancement Pattern ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct

MR imaging of hepatic metastasis in patients with malignant melanoma: Evaluation of suspected lesions screened at contrast-enhanced CT

2012 ◽  
Vol 81 (4) ◽  
pp. 714-718 ◽  
Author(s):  
Keitaro Sofue ◽  
Ukihide Tateishi ◽  
Masakatsu Tsurusaki ◽  
Yasuaki Arai ◽  
Naoya Yamazaki ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Mr Imaging ◽  
Hepatic Metastasis ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct

scholarly journals The Role of PET-CT in Gastric Cancer – A Narrative Review

2020 ◽  
Author(s):  
Raluca-Ioana Dascălu ◽  
Dan Nicolae Păduraru ◽  
Alexandra Bolocan ◽  
Daniel Ion ◽  
Octavian Andronic
Keyword(s):  
Gastric Cancer ◽  
Fdg Pet ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Enhanced Ct ◽  
Increasing Risk ◽  
Gastric Cancer Patients ◽  
Fdg Pet Ct

Background: Gastric cancer is one of the most common and leading causes of cancer death worldwide, with an increasing risk and prevalence. Although the usage of 18-FDG PET-CT in gastric cancer evaluation remains a matter of debate and is not consistently recommended by international guidelines, our descriptive review aims to highlight its actual role in the diagnostic accuracy, staging, therapeutic management, and relapse monitoring of this malignancy. Methods: The current research was conducted using scholarly databases including PubMed, Scopus, and Google Scholar by searching useful science journals, references, and abstracts on the topic. The keywords used were “gastric cancer” AND “PET-CT”. Results: 18-FDG PET-CT remains a promising method with increasing clinical utility not only across a wide variety of malignancies, but also among gastric cancer patients. Conclusions: We are certain that with further improvements, this technique could improve the diagnosis and evaluation of gastric cancer, and make it more approachable and accurate. Keywords gastric cancer (GC), PET-CT, 18-FDG PET-CT, 18F-FDG uptake, ceCT (contrast-enhanced CT)

scholarly journals Intratumoral and Peritumoral Radiomics of Contrast-Enhanced CT for Prediction of Disease-Free Survival and Chemotherapy Response in Stage II/III Gastric Cancer

2020 ◽  
Vol 10 ◽  
Author(s):  
Junmeng Li ◽  
Chao Zhang ◽  
Jia Wei ◽  
Peiming Zheng ◽  
Hui Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Disease Free Survival ◽  
Stage Ii ◽  
Chemotherapy Response ◽  
Free Survival ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Disease Free ◽  
Radiomics Signature

BackgroundWe evaluated the ability of radiomics based on intratumoral and peritumoral regions on preoperative gastric cancer (GC) contrast-enhanced CT imaging to predict disease-free survival (DFS) and chemotherapy response in stage II/III GC.MethodsThis study enrolled of 739 consecutive stage II/III GC patients. Within the intratumoral and peritumoral regions of CT images, 584 total radiomic features were computed at the portal venous-phase. A radiomics signature (RS) was generated by using support vector machine (SVM) based methods. Univariate and multivariate Cox proportional hazards models and Kaplan-Meier analysis were used to determine the association of the RS and clinicopathological variables with DFS. A radiomics nomogram combining the radiomics signature and clinicopathological findings was constructed for individualized DFS estimation.ResultsThe radiomics signature consisted of 26 features and was significantly associated with DFS in both the training and validation sets (both P<0.0001). Multivariate analysis showed that the RS was an independent predictor of DFS. The signature had a higher predictive accuracy than TNM stage and single radiomics features and clinicopathological factors. Further analysis showed that stage II/III patients with high scores were more likely to benefit from adjuvant chemotherapy.ConclusionThe newly developed radiomics signature was a powerful predictor of DFS in GC, and it may predict which patients with stage II and III GC benefit from chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document